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1. Introduction
Glioblastoma multiforme (GBM) is the most common primary brain tumor among adults.
Rapid tumor progression and diffuse invasion of brain tissue restrict the therapeutic options
and result in poor prognosis despite advances in the understanding of this tumor’s molecular
biology and pathophysiology [1-4]. Current standard therapy consists of a combination of
tumor resection, irradiation and temozolomide. Advances in the field of molecular biology
have led to the development of targeted therapy, and the epidermal growth factor receptor
(EGFR) has been introduced as one potential therapeutic target [5]. Although pre-clinical
studies have shown promising effects, clinical applications yielded no significant benefit in
comparison with standard therapy. This fact encouraged extensive investigations studying the
molecular mechanisms underlying GBM resistance to EGFR-targeted therapy. Epithelial to
mesenchymal transition (EMT) is considered an important factor contributing to resistance
towards this therapy by diminishing the molecular target [1-6].
Epithelial to mesenchymal transition is a common process, taking part in organ development,
wound healing, tissue remodelling, cancer progression and metastasis. The main features
accompanying this mechanism are the loss of epithelial characteristics of cells and the acquis‐
ition of mesenchymal markers such as fibronectin, vimentin and N-cadherin. As a result, tumor
cells develop increasing invasive and migratory potential. The loss of epithelial features
mounts the resistance of tumor cells against targeted therapy directed towards the EGFR.
Mesenchymal transition leads to disorganisation of the cytoskeleton, disruption of intercellu‐
lar adhesions and changes in expression of transcriptional factors, resulting in the development
of a more malignant cellular phenotype [1, 2, 7].
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In embryogenesis, epithelial to mesenchymal transition appears during gastrulation and
activates the formation of the mesodermal layer as the third germ layer after ectoderm and
endoderm are built. In addition, EMT is involved in the development of neural crest cells,
arising from the dorsal part of the neural tube [7]. This requires a highly specialised program
that is necessary to allow the normal development of cells. On the other hand, under patho‐
logical conditions, EMT increases the invasiveness and migratory potential of tumor cells,
supports their malignant transformation and may lead to resistance of tumor cells towards
various therapeutic agents, especially in malignant gliomas.
2. EGFR
The EGFR is a transmembraneous glycoprotein belonging to the human EGFR (HER) family,
which includes four members (HER 1-4) that share a similar structure. The EGFR/HER1
consists of external and internal domains. The extracellular part possesses a binding sequence
for ligands such as EGF, hepatocyte growth factor (HGF), fibroblast growth factor (FGF),
insulin-like growth factor-1 (IGF-1) or tumor growth factor-α (TGF-α). The internal domain
contains a tyrosine kinase (TK), capable of phosphorylation and activation of a variety of
downstream pathways such as phospholipase Cγ, phosphatidylinositol-3-kinase (PI3-K),
Janus-activated kinase 2 (JAK-2) and mitogen-activated kinase (MAPK). Human epidermal
growth factor family receptors are expressed on many cell types and mediate signal transduc‐
tion to intracellular compartments and hereby regulate various functions of cells such as
proliferation or differentiation [1, 5, 8, 9].
Phosphorylation and dephosphorylation are crucial pathophysiological events within
intracellular interactions. A dysregulation of their balance contributes to the development of
an invasive cellular phenotype. Upon activation, receptor tyrosine kinases dimerise and
autophosphorylate on tyrosine residues, which in turn create complexes with proteins
possessing SH2 domains such as GRB2, SHC or signalling proteins PI3-K and SRC [9].
Pathological activation of RAS occurs in numerous cancers. This signalling pathway inte‐
grates various diverse stimuli promoting cell transformation, gene expression and tumor
progression. RAS is a small guanine triphosphate-binding protein that activates the serine-
threonine kinase RAF. RAF phosphorylates the dual specificity kinase MEK, which in turn
activates MAPK (ERK). The latter translocate into the nucleus and activate various tran‐
scription factors such as the ETS family factors FOS, JUN or SLUG (SNAI-2). Thereby RAS
propagates the activation of EMT. Moreover, RAS is able to promote EMT by downstream
activation of PI3-K or RHO/RAC. PI3-K is involved in cell cycle regulation via phosphory‐
lation of cyclin-dependent kinase inhibitors. In addition, it controls the phosphorylation of
proapoptotic proteins and survival of the cell. PI3-K can be activated either via RAS or di‐
rectly via TK receptors. PI3-K is a lipide kinase, and its activation generates phosphatidyli‐
nositol-3,4,5-triphosphate (PIP3) at the inner side of plasma membrane, which furthermore
mediates the signalling via the serine-threonine kinase AKT that is able to translocate into
the nucleus and take part in gene regulation through phosphatidylinositol-dependent pro‐
tein kinase-1 (PDK-1) [8, 9, 10].
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Epidermal growth factor overexpression and/or mutational activation is the most common
molecular alteration in primary GBM and can be detected in far more than 50% of glioblastoma
cells [5]. There are several mechanisms that may cause dysfunction of the receptor. Epidermal
growth factor receptor gene amplification is the most common reason leading to protein
overexpression. Other mechanisms include constitutive receptor activation by deletion-
mutation (EGFRvIII) or autocrine overproduction of EGFR ligands [5, 6, 9]. The presence of
EGFRvIII is associated with EGFR gene amplification.
3. Therapeutic EGFR inhibitors
Several drugs that target EGFR have been introduced. The TK inhibitors erlotinib and gefitinib
compete with adenosine triphosphate to bind to the intracellular TK domain and dissolve
further signalling involving PI3-K/AKT and MAPK pathways. Erlotinib was approved in the
treatment of metastatic non-small cell lung carcinoma (NSCLC) and in combination with
gemcitabine for metastasized pancreatic cancer or pancreatic cancer without the possibility of
gross total resection [11, 12]. Gefitinib is used for metastatic NSCLC. Another small molecule
EGFR-TK inhibitor represents lapatinib, which affords dual inhibition of EGFR and HER-2
and has been approved for the treatment of advanced or metastatic breast cancer. Unfortu‐
nately, the clinical application in gliomas had shown no benefit in comparison to standard
therapy [1, 5, 6, 8].
Another possibility to inhibit EGFR signalling consists in the prevention of ligand binding.
Monoclonal antibodies such as cetuximab have been introduced and investigated for this
purpose. However, their molecular weight impairs their penetration of the blood brain barrier.
Often the concentration of the agent is insufficient to yield a significant therapeutic effect
within the targeted tissue [13].
Antisense RNA has been introduced as an option to inhibit the EGFR pathway as well. Sense
RNA hybridizes to antisense RNA which leads to inhibition of translation. Another strategy
to switch off the EGFR cascade is the application of small interfering RNAs. These suppress
the homolog genes and result in sequence-specific degradation of mRNA. Furthermore,
ribozymes are small RNA molecules that are able to bind and cleave complementary RNA
substrates. EGFRvIII-targeted ribozymes have been reported to reverse malignant phenotype
of transformed fibroblasts and glioblastoma cells [14, 15]. However, the potential clinical value
of these methods remains unknown [16].
4. Molecular principles of EMT
Tumor progression represents an integrated multistep complex of molecular changes that
ultimately result in local invasion and dissemination of malignant cells.  The cells invade
the epithelial basement membrane, infiltrate the surrounding tissue, access the blood circu‐
lation and may create new tumor seeds.  This dynamic and aggressive process demands
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cell-to-cell and cell-to-matrix interactions, degradation and remodelling of extracellular ma‐
trix, cytoskeleton reorganisation and gain of migratory behaviour of tumor cells. Epithelial
to mesenchymal transition is a differentiation switch which promotes the loss of the epithe‐
lial phenotype and facilitates cell motility and invasiveness. One of the crucial steps pro‐
moting EMT is  the  repression of  the  epithelial  marker  E-cadherin,  a  transmembraneous
calcium-dependent glycoprotein responsible for cell-cell adhesion, which plays a key role
in embryonic development and homeostasis. The intracellular domain of E-cadherin asso‐
ciates with a protein complex involving α-catenin, β-catenin and p120-catenin. Actin pro‐
teins bind α-catenin and hereby allow the connection between E-cadherin and the actin
microfilament network of the cytoskeleton that forms the shape of the cell. Epithelial cells
are typically characterized by apicobasal difference. Thus, the apical compartment faces the
lumen, whereas the basolateral surface is located on a basement membrane. Epithelial cells
are anchored by specialized cell-to-cell connections, i.e. tight junctions, adherens junction
and desmosomes. E-cadherin acts as a tumor suppressor by linking the epithelial cells and
keeping them in a stationary rigid state [1, 2, 7, 8, 9, 17].
During EMT, tumor cells loose junctional contact and epithelial cell polarity and acquire typical
properties of mesenchymal cells. E-cadherin is a central regulator of the epithelial phenotype,
and its downregulation results in the destabilisation of the epithelial architecture. Dysregula‐
tion of E-cadherin may be located at various levels, and hypermethylation of the E-cadherin
promoter is among the molecular mechanisms [1, 2, 8-10, 17].
Under normal physiological conditions, epithelial cells are separated from the extracellular
matrix (ECM) by basement membranes. This barrier prevents the interaction between epithe‐
lial cells and their microenvironment. The destabilisation of the basement membrane enables
contact between various signalling proteins of the ECM and epithelial cells. The resulting
cellular signalling may enhance the progression of EMT by activating different intracellular
signalling pathways [17]. Gene transcription regulated by transcription factors is an important
mechanism involved in gene regulation. Some transcriptional repressors such as SNAI-1/2,
zinc finger E-box binding homeobox-1 (ZEB-1) and ZEB-2 are able to bind directly to the E-
cadherin promoter and repress its transcription. Overexpression of these proteins supports
mesenchymal transformation and the change of behavioural characteristics and promotes the
continuous acquisition of malignant features by tumor cells [18, 19]. Crucial transcription
factors involved in EMT are TWIST-1 and signal transducers and activators of transcrip‐
tion-3/-5 (STAT-3/-5). TWIST-1 is a basic helix-loop-helix protein that forms heterodimers
binding on DNA, hereby regulating the development and differentiation of cells. For instance,
TWIST-1 inhibits p53-mediated apoptosis in rodent fibroblasts or stops normal skeletal muscle
development by creating heterodimers with myogenic basic helix-loop-helix proteins (MyoD
and myogen). Its function within EMT is repression of the epithelial marker E-cadherin,
activation of N-cadherin and hereby promotion of mesenchymal transformation, resulting in
a more aggressive phenotype and progression of glioblastoma. TWIST-1 is reported to be an
important EMT regulator in other malignancies as well, such as breast, gastric, hepatocellular
and prostate cancer. There is significant evidence that TWIST-1 is involved in regulation of
programmed cell death and induction of apoptosis. Through inhibition of p53-mediated
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apoptosis, TWIST-1 enables cell survival by preventing growth arrest and promotes invasive‐
ness of tumor cells [3, 4]. Moreover, this process may result in increased resistance to various
chemotherapeutic agents.
Sex determining region Y-box-2, also known as SOX-2, is another transcription factor that is
co-expressed with TWIST-1, playing an important role during the development of the nervous
system and tumor progression. Knockdown of SOX-2 results in reduced expression of TWIST-1
[4], promoting EMT and potentially being essential for tumor progression and the develop‐
ment of tumor resistance to EGFR-targeted therapies.
Signal transducer and activator of transcription-3 activation is associated with more malig‐
nant tumors and poor prognosis. Its overexpression has been detected in malignant glio‐
mas,  and  its  activation  correlates  with  glioma  grade.  The  STAT  protein  family  is
phosphorylated  by  receptor-associated  kinases  and  builds  homo-  or  heterodimers  that
translocate to the cell nucleus and play a crucial role in cell cycle progression, EMT, anti-
apoptosis and metastasis. Signal transducer and activator of transcription-3 is hereby con‐
sidered an important factor mediating and converging many cellular pathways. Therefore,
either direct or indirect inhibition of STAT-3 may represent an optional therapeutic target
in gliomas. Moreover, STAT-3 interacts with EGFR and mediates TWIST-1 expression and
TWIST-1-mediated EMT. In addition, there seems to be a correlation between EGFR/EGFR‐
vIII expression, activation of STAT-3 and glioma grade. Noteworthy, a nuclear interaction
between EGFRvIII and STAT-3 leads to malignant transformation of glioma cells [20].
Another interesting point is a recent discovery, described by Lo. He found increased expression
of the pro-inflammatory gene cyclooxygenase-2 (COX-2) activated by EGFR-EGFRvIII and
STAT-3 cooperation [21]. These interactions represent potential factors contributing to
increased resistance of GBM to EGFR-targeted therapy. The important inflammatory enzyme
COX-2 is overexpressed in various malignancies. In NSCLC, it has been reported that increased
levels of COX-2 contribute to apoptosis resistance, angiogenesis and invasiveness of tumor
cells. The effector of COX-2 is prostaglandin E-2 (PGE-2) which is produced by tumorous
stromal cells and reduces the expression of E-cadherin via ZEB-1 and SNAI-1. Prostaglandin
E-2 activates four G-protein coupled receptors, also known as E-prostanoid receptors-1 to -4
(EP-1 to EP-4), and promotes signalling via the MAPK/ERK cascade, which finally upregulates
SNAI-1 and ZEB-1 expression [1, 21, 23]. This loop enhances signalling in the same pathway
that is activated by EGFR. In addition, low levels of E-cadherin have been reported to be
associated with increased resistance to EGFR-TK inhibitors in NSCLC [21, 23].
Signal transducer and activator of transcription-5 represents an important transcription fac‐
tor which is involved in the regulation of many genes, facilitating cellular growth, migra‐
tion and motility. Dimers of STAT-5 bind to specific DNA promoter regions and mediate
cellular gene responses. Dysregulation of STAT-5 has been recently described in many ma‐
lignancies  such  as  prostate,  breast  and  squamous  cell  cancer  of  the  head  and  neck
(SCCHN). In SCCHN, the activity of STAT-5 results in increased resistance of tumor cells
to erlotinib. Moreover, it confers decreased apoptosis following treatment with cisplatin, fi‐
nally diminishing the clinical effect [19].
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The SNAI family members (SNAI-1-3) are related transcriptional repressors. Their SNAG
domain at the N-terminal region is responsible for their activity, and their zinc-finger C-
terminal region enables the attachment to specific DNA sequences. The main role of SNAI
genes is the regulation and promotion of E-cadherin expression. It has been reported that
knockdown of SNAI-1 results in decreased invasion and migration of glioma cells. Moreover,
SNAI-1 induces expression of matrix metalloprotease-2 (MMP-2), another contributor to EMT
progression [18].
Zinc finger E-box binding homeobox-1 regulates transcription of E-cadherin by binding of two
zinc finger domains to two E-boxes located in the E-cadherin promoter region. It has been
shown that low levels of ZEB-1 improve the sensitivity of cells to erlotinib in head and neck
squamous cell carcinoma cell lines [21].
Figure 1. Signal transduction pathways associated with EMT. Abbreviations: APC – adenomatous polyposis coli, EMT -
epithelial to mesenchymal transition, TGF-β – transforming growth factor β, EGF – epidermal growth factor, EGFR -
epidermal growth factor receptor, FGF – fibroblast growth factor, GSK 3 – glycogen synthase kinase, HGF – hepatocyte
growth factor, IGF – insulin-like growth factor, ILK – integrin-linked kinase, MAPK - mitogen-activated protein kinase,
MEK - mitogen-activated protein kinase kinase, MMPs - matrix metalloproteases, PI3K – phosphoinositide 3-kinase,
RTK – receptor tyrosine kinase.
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Activator protein-1 (AP-1) is a protein complex consisting of JUN and FOS heterodimers or
JUN homodimers. It plays an important role in the regulation of a variety of genes, resulting
in the progression of EMT. Induction of AP-1 correlates with MAPK-activation and phos‐
phorylation of the ETS family transcription factors such as E twenty-six-like transcription
factor (ELK-1) which furthermore induces the transcription of FOS. Phosphorylated ETS
factors result ultimately into the repression of E-cadherin and up-regulation of genes that lead
to the transcription of MMPs [2].
As a result of downregulation of E-cadherin, loss of cell-to-cell adhesions and reorganisation
of the actin cytoskeleton during EMT, cells acquire a mesenchymal identity. The expression of
mesenchymal cytoskeleton proteins such as vimentin and the deposition of ECM proteins such
as collagen or fibronectin become dominant and stimulate the activation of integrins and their
signalling pathways that promote the migratory potential of cells. Moreover, it has been
reported that the level of E-cadherin depends on the phosphorylation state of β-catenin.
Tyrosine phosphorylation of β-catenin prevents the binding to E-cadherin and favours the loss
of intercellular contact [1, 2, 17].
Endocytosis and proteolytic cleavage of the extracellular domain of E-cadherin are other
factors contributing to destabilisation of intercellular adhesion complexes, cell dissociation
and EMT. In addition, integrins together with TK receptor activity contribute to the acquisition
of an invasive phenotype via SRC. SRC is a non-receptor, SH2-containing cytoplasmic TK
which participates in the control of adhesion and migration. SRC signalling contributes to the
alteration of the balance between the adhesive and migratory states of cells. SRC stimulates
focal adhesion kinase (FAK) that in turn mediates MAPK signalling, leading to the phosphor‐
ylation of light chain kinase which ultimately creates phosphomyosin, resulting in increased
cell motility and the disorganisation of cell-to-cell adhesions. In addition, SRC is involved in
the regulation of numerous proteins of the ECM such as vinculin or paxillin [2, 17].
5. Cancer stem cells
Cancer stem cells have been introduced as cell colonies able to self-renew, proliferate and
produce heterogeneous lineages of cancer cells. Hereby they are playing a crucial role in tu‐
mor initiation, growth, invasion and recurrence. Epithelial to mesenchymal transition pro‐
motes the development of cancer stem-like cells that exhibit mesenchymal phenotypes and
acquire multipotent features.  Recent studies have provided the evidence of  glioma stem
cells or brain tumor stem cells [22]. These exhibit a similar phenotype as neural stem cells
and in the majority of cases are characterized by surface proteins such as CD133 or nestin
[23, 24]. This type of cells exhibits radio-resistance and an abnormal growth pattern. Tumor
recurrence is the primary consequence of treatment failure and cause of death in patients
suffering from malignant gliomas. Glioma stem cells possess the potential to stimulate the
survival of transformed cells and thereby may become a useful therapeutic target [23, 24].
However,  a profound understanding of the biological features of these cells will  require
many more studies.
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6. Extracellular matrix and EMT
Tumor cells express matrix metalloproteases (MMPs) which are able to dissolve the ECM and
thereby promote tumor invasion, migration and metastasis. Matrix metaloproteases are a
group of zinc-dependent endoproteases. Matrix metalloprotease-2 (MMP-2) and MMP-9 are
regulated by SNAI-1 and SNAI-2 (SLUG). Epithelial to mesenchymal transition-mediated
dysregulation of SNAI-1 and SLUG in turn promotes the activity of MMP-2 and MMP-9 and
thereby increases the invasive and migratory activity of tumor cells. Thus, cancer cells
undergoing EMT enhance the initiation of metastasis, often involving transforming growth
factor-β (TGF-β) and SMAD, and represent a phenotypic subpopulation of cancer cells which
promote the dissemination of the malignant disease. Stromelysin, known as MMP-3, promotes
EMT through the induction of reactive oxygen species (ROS) that, in turn, results in overex‐
pression of SNAI [2, 8-10, 17].
7. TGF–β
Transforming growth factor-β has been reported as a strong inducer of EMT. This protein
belongs to the TGF-β superfamily and exhibits three isoforms, i.e. TGF-β1, TGF-β2 and TGF-
β3, all of which are involved in cell proliferation and differentiation. Transforming growth
factor-β is able to induce apoptosis in numerous cell types via the Smad pathway. In addition,
TGF-β may recruit non-Smad signalling, for instance the MMP cascade, to promote the
malignant transformation of cells. The TGF-β response results in Smad 2 and Smad 3 activation
through C-terminal phosphorylation [7, 8].
Transforming growth factor-β signalling finally regulates the expression of SNAI, ZEB and
TWIST proteins that, in turn, influence the expression of proteins such as claudin, desmo‐
plakin, MMPs or fibronectin. In this context, TGF-β functions as an important regulator of
EMT [7, 8].
Promoted by TGF-β, SNAI-1 and SNAI-2 (SLUG) levels are increased during EMT. Hepatocyte
growth factor, FGF and EGF induce the RAS-MAPK or PI3K-AKT pathways that lead to the
activation of SNAI expression. The increased expression of SNAI-1 or SNAI-2 enhances the
expression of vimentin and fibronectin, reduces E-cadherin and plakoglobin levels and hereby
switches on mesenchymal transformation. During embryological development, this process
takes care of mesodermal layer and neural crest development. In addition, SNAI proteins
inactivate a variety of epithelial proteins such as occludin and claudin. SNAI-1 represses the
expression of claudin 3, claudin 4 and claudin 7 and regulates the expression of desmosome
proteins such as desmoplakin. SNAI-1 and SNAI-2 decrease the expression level of claudin 1
and occludin. Furthermore, increased SNAI protein activity stimulates the expression of
mesenchymal proteins such as Rho-like GTPases which are composed of RHO, RAC and
CDC-42 proteins that influence cytoskeleton architecture and cell motility. RHO and RAC
regulate E-cadherin activity and adhesiveness of cells, and their activity is among the impor‐
tant determinants of EMT. TGF-β activates the signalling cascade downstream of RHO. The
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main RHO effector in TGF-β response is ROCK activity which regulates different processes
involved in cell migration such as cytoskeleton reorganisation [1, 2, 7, 8, 17, 18].
Transforming growth factor-β activates TK receptors via PI3-K that, in turn, controls AKT
in diverse cells. AKT is an important regulator of various signalling cascades, controlling
cell survival, migration and proliferation. Activation of the PI3K-AKT cascade plays a cru‐
cial role in EMT.
The WNT protein plays a significant role in the process of mesenchymal transformation as
well. WNT is connected downstream to β-catenin, builds adherens junctions and connects E-
cadherin to the cytoskeleton through α-catenin. The WNT glycoprotein binds to the trans‐
membraneous Frizzled receptor that activates Dishevelled, which in turn prevents
phosphorylation of β-catenin by inhibition of glycogen synthase kinase-3β (GSK-3β) and
hereby stops its ubiquitination and degradation. This step increases the level of cytoplasmic
β-catenin that ultimately translocates into the nucleus and builds complexes with T-Cell factor
(TCF) and lymphoid enhancer factor-1 (LEF-1). These related transcription factors mediate the
gene response by activating genes required for EMT such as SLUG, ETS and JUN or fibronectin
and vimentin. In addition, the basic feature of EMT, downregulation of E-cadherin, increases
the level of cytosolic free β-catenin itself. Similarly, the activation of PI3K-AKT and integrin-
linked kinase (ILK) inhibits GSK-3β and leads to the accumulation of β-catenin. This inhibitory
effect is responsible for the upregulation of SNAI, which normally is negatively regulated by
the activation of GSK-3β. The process contributes significantly to the destabilisation of
epithelial adhesiveness and promotes the acquisition of the mesenchymal phenotype with
increased cell motility and invasiveness [2, 27].
8. Nuclear factor–κB
Nuclear factor-κB (NF-κB) belongs to a family of transcriptional factors, whose activity is
important for the maintenance and promotion of the invasive phenotype in cancer cells.
Nuclear factor-κB binds DNA sequences as hetero- or homodimers and consequently regulates
various cellular processes. Several genes encoding proteins that are involved in the cell cycle
(Cyclin D1, c-MYC), cell adhesion (vascular cell adhesion protein) or inflammation (interleu‐
kin-2, interleukin-6, interleukin-8) are regulated in this way. Even if NF-κB is ubiquitous, its
activity is detected mostly in mature B-lymphocytes [28, 29].
The inhibitor protein IκB plays a crucial role in the degradation of NF-κB and has been
discovered  in  breast  cancer.  Signalling  via  NF-κB  results  in  increased  expression  of
SNAI-1 and hereby contributes to EMT progression. Moreover, the activity of NF-κB cor‐
relates with the expression of ZEB-1, ZEB-2 and TWIST, which are other strong inducers
of EMT [28].
Vimentin,  a  56-kDa intermediate  filament  protein,  contributes  to  mesenchymal  transfor‐
mation  of  the  cell.  Cells  acquire  a  spindle-shape  form  and  loosen  their  connections  to
neighbouring  cells.  Studies  of  vimentin-knockdown  mice  have  shown  significantly  re‐
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duced wound healing abilities.  In addition,  vimentin expression promotes the migration
of cancer cells. Nuclear factor-κB activates the vimentin promoter and thus increases the
expression of vimentin [28].
9. Resistance to EGFR–targeted therapy
Epithelial to mesenchymal transition is considered an important factor contributing to the
resistance of glioma cells against EGFR-targeted therapy. On the other hand, alternative
potential explanations of this phenomenon have been suggested.
Glioblastomas exhibit a high degree of intrinsic heterogeneity with a variety of signalling
pathways that mediate the subcellular actions. In the case of EGFR inhibition, alternative
downstream pathways may be activated and potentiated. A functional-switch could lead to
the survival of the cells and, by clonal selection, to the acquisition of resistance to specific
therapeutic agents that inhibit one specific signalling pathway.
Phosphatase and tensin homolog is a tumor suppressor protein which dephosphorylates
phosphatidylinositol (3, 4, 5)-triphosphate and hereby negatively regulates the AKT signalling
axis. Phosphatase and tensin homolog is often mutated in GBM cells which promotes the
activity of mTOR resulting in tumor progression. The inhibition of this dominant pathway
may lead to alteration of the hierarchy in TKs such as platelet-derived growth factor receptor
(PDGFR), JAK2 or cellular mesenchymal-epithelial transition factor (c-MET) [9, 29]. Platelet-
derived growth factor receptor is the second most common TK receptor amplified in GBMs.
Moreover, MET is also amplified in some GBMs. Concomitant presence of gene amplifications
within GBMs may activate and potentiate alternative signalling pathways during inhibitory
targeting of EGFR and hereby contribute to increased resistance of glioma cells to erlotinib or
other TK-inhibitors [29].
10. Conclusion
The EGFR has been introduced as a therapeutic target in some malignancies. Unfortunately,
in GBM, there has been no demonstrable benefit of this approach in comparison to standard
therapy. Epithelial to mesenchymal transition is considered an important factor contributing
to failure of this therapy by diminishing the molecular target. This phenomenon leads to the
loss of epithelial characteristics of cells and to the expression of mesenchymal features. The
acquisition of increased motility and invasiveness by glioma cells represents an essential
prerequisite for subsequent tumor recurrence and malignant progression. Epithelial to
mesenchymal transition is primarily regulated through signalling pathways affecting E-
cadherin, a transmembraneous protein responsible for intercellular cell contact. Molecular
changes are promoted by a variety of external stimuli. The identification and better under‐
standing of these processes may enable the development of new therapeutic strategies
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